The cost of allogeneic red blood cells -: a systematic review

被引:46
作者
Amin, M
Fergusson, D
Aziz, A
Wilson, K
Coyle, D
Hébert, P
机构
[1] Univ Ottawa, Ctr Transfus Res, Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON K1H 8L6, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] Univ Ottawa, Dept Community Med, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Med, Ottawa, ON, Canada
关键词
allogeneic; blood; cost; red blood cells;
D O I
10.1046/j.1365-3148.2003.00454.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several reports suggest that the cost of RBCs may have risen over time, but there exists very little published evidence of that. The objective was to determine whether published studies documenting cost data on RBCs suggest an increase over time and to assess the quality of cost studies. We used the terms 'cost', 'allogeneic/allogenic' and 'blood' to identify cost studies between 1966 and 2002 from Medline, ISIesource and Ingenta electronic databases. Furthermore, we manually searched a number of transfusion and health economics journals for completeness. We included studies that used an established methodology and conducted an economic evaluation using primary/secondary cost data to calculate the cost of RBCs and RBC transfusion. Studies without allogeneic RBCs as comparator were excluded. Two individuals independently reviewed the studies and included studies upon reaching a consensus. Fourteen studies qualified the selection criteria and were included in the review. Ten studies were identified from Medline, two from Ingenta, one from ISIesource and one was a conference paper. Of the 14 studies reviewed, 10 had focused on RBC transfusion and four had focused on both RBCs and RBC transfusion. Ten studies were from the US, and two each from Canada and the UK, respectively. Two studies had explicit objective of cost calculation, and others had calculated costs towards fulfilling other objectives. Most of the reviewed studies were dated and of poor quality. Despite these limitations, it appears that the cost of RBCs has increased over time in the UK, Canada and the US. More studies are needed to fully assess the trend of costs over time. Future cost studies should try to follow the economic evaluation guidelines for greater research implications.
引用
收藏
页码:275 / 285
页数:11
相关论文
共 24 条
[1]  
*ARCS, 2002, ANN REP AM RED CROSS
[2]   Evaluating the appropriateness of red blood cell transfusions: The limitations of retrospective medical record reviews [J].
Audet, AM ;
Goodnough, LT ;
Parvin, CA .
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 1996, 8 (01) :41-49
[3]   A cost analysis of autologous and allogeneic transfusions in hip-replacement surgery [J].
Blumberg, N ;
Kirkley, SA ;
Heal, JM .
AMERICAN JOURNAL OF SURGERY, 1996, 171 (03) :324-330
[4]  
Bopp MKF, 2001, TRANSFUSION MED, V11, P149
[5]  
BURR JT, 1990, QUAL PROG, V2, P13
[6]   Costs of blood transfusion: A process-flow analysis [J].
Cantor, SB ;
Hudson, DV ;
Lichtiger, B ;
Rubenstein, EB .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2364-2370
[7]   Cost of outpatient blood transfusion in cancer patients [J].
Crémieux, PY ;
Barrett, B ;
Anderson, K ;
Slavin, MB .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2755-2761
[8]  
DRANITSARIS G, 2000, J ONCOLOGY PHARM PRA, V6, P37
[9]   Guidelines for authors and peer reviewers of economic submissions to the BMJ [J].
Drummond, MF ;
Jefferson, TO .
BRITISH MEDICAL JOURNAL, 1996, 313 (7052) :275-283
[10]  
Drummond MF, 2015, Methods for the Economic Evaluation of Health Care Programmes, V4th, DOI DOI 10.1016/S0749-3797(97)00069-X